Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
URGN
#2452
UroGen Pharma Ltd. Ordinary Shares
21.055
0
USD
-0.78%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-0.78%
Monthly Change
+11.82%
6 month change
+10.82%
Year Change
+10.82%
Previous Close
21.220
0
Open
20.865
0
Bid
Ask
Low
20.865
0
High
21.390
0
Volume
60
Markets
US Stock Market
Healthcare
URGN
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
22.27 M
22.67 M
23.44 M
34.12 M
46.09 M
48.68 M
—
Valuation ratios
Enterprise value
348.49 M
171.21 M
244.66 M
522.55 M
441.4 M
1.15 B
3.31 B
Price to earnings ratio
—
—
-1.79
-4.29
-3.6
-7.34
-20.71
Price to sales ratio
—
—
3.52
6.45
5.86
11.93
37.73
Price to cash flow ratio
—
—
-2.25
-5.74
-4.72
-6.94
-23.5
Price to book ratio
—
—
-2.21
-6.73
-51.87
-10.68
24.82
Enterprise value to EBITDA ratio
-2.75
-1.87
-2.86
-6.6
-4.05
-8.17
-23.78
Profitability ratios
Return on assets %
-1.05
-0.93
-0.81
-0.57
-0.44
-0.77
-0.73
Return on equity %
-1.33
-13.17
1.23
1.57
14.41
1.46
2.02
Return on invested capital %
-1 304.03
-2 060.7
-1 538.17
-1 158.23
-1 526.09
-1 244.1
-1 789.5
Gross margin %
91.45
89.27
101.4
107.87
104.67
103.07
415.45
Operating margin %
-1 074.15
-192.11
-141.35
-96.38
-124.28
-132.21
-604.15
EBITDA margin %
-1 074.29
-190.38
-154.79
-116.84
-139.98
-149.57
-679.23
Net margin %
-1 088.94
-230.67
-196.33
-150.36
-162.92
-162.53
-735.25
Liquidity ratios
Quick ratio
5.3
4.9
5.21
5.24
5.81
3.65
16.9
Current ratio
5.39
5.11
5.39
5.42
6.01
4.01
17.78
Inventory turnover
—
—
0.19
0
—
—
—
Asset turnover
0.07
0.4
0.44
0.43
0.34
0.39
0.45
Solvency ratios
Debt to assets ratio
—
—
0.72
0.55
0.43
0.62
2.37
Debt to equity ratio
—
—
-1.09
-1.51
-13.91
-1.17
-6.21
Long term debt to total assets ratio
—
—
0.72
0.55
0.43
0.61
2.35
Long term debt to total equity ratio
—
—
-1.09
-1.51
-13.83
-1.16
-6.16
Per share metrics
Operating cash flow per share
—
—
-3.84
-2.65
-2.26
-3.38
-3.4
EBIT per share
—
—
-3.84
-2.78
-2.55
-2.94
-2.96
EBITDA per share
—
—
-3.8
-2.76
-2.54
-2.94
-2.96
Total debt per share
—
—
4.28
3.42
2.86
2.57
10.31
Cash per share
—
—
4.38
4.91
5.64
2.5
12.77
Net current asset value per share
—
—
5.65
5.87
6.44
3.87
16.5
Tangible book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-7.53
Working capital per share
—
—
4.6
4.79
5.37
2.9
12.77
Book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-7.53
News
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation
Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts
Palantir and AeroVironment among market cap stock movers on Monday
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
UroGen Pharma earnings missed by $0.06, revenue fell short of estimates
UroGen reports $15.8M in ZUSDURI sales, refinances debt
UroGen refinances debt with $250M facility at 8.25% rate
UroGen faces earnings test as ZUSDURI launch ramps
UroGen Pharma CMO Schoenberg sells $145k in shares